80 related articles for article (PubMed ID: 16490026)
1. Early treatment of cavernositis resulted in erectile function preservation.
Shamloul R; Kamel I
J Sex Med; 2006 Mar; 3(2):320-2. PubMed ID: 16490026
[TBL] [Abstract][Full Text] [Related]
2. A broken intracavernous needle: successful ultrasound-guided removal.
Shamloul R; Kamel I
J Sex Med; 2005 Jan; 2(1):147-8. PubMed ID: 16422918
[TBL] [Abstract][Full Text] [Related]
3. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
[TBL] [Abstract][Full Text] [Related]
4. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy.
Yiou R; Cunin P; de la Taille A; Salomon L; Binhas M; Lingombet O; Paul M; Abbou C
J Sex Med; 2011 Feb; 8(2):575-82. PubMed ID: 20807323
[TBL] [Abstract][Full Text] [Related]
5. Cavernositis following intracavernous injection of vasoactive drugs.
Vives A; Collado A; Ribé N; Segarra J; Ruiz Castañé E; Pomerol JM
Urol Int; 2001; 67(1):111-2. PubMed ID: 11464134
[TBL] [Abstract][Full Text] [Related]
6. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
Tang SF; Chu NK; Wong MK
Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
[TBL] [Abstract][Full Text] [Related]
7. Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1.
Godschalk M; Gheorghiu D; Katz PG; Mulligan T
J Urol; 1996 Sep; 156(3):999-1000. PubMed ID: 8709384
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
9. Intracorporeal needle breakage as an unusual complication of intracavernous self-injection.
Iacono F; Barra S
Tech Urol; 1998 Mar; 4(1):54-5. PubMed ID: 9568779
[TBL] [Abstract][Full Text] [Related]
10. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
[TBL] [Abstract][Full Text] [Related]
11. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
Chen RN; Lakin MM; Montague DK; Ausmundson S
J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
[TBL] [Abstract][Full Text] [Related]
12. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment.
Alexandre B; Lemaire A; Desvaux P; Amar E
J Sex Med; 2007 Mar; 4(2):426-31. PubMed ID: 17367438
[TBL] [Abstract][Full Text] [Related]
13. Multiple retained needles: an unusual complication of intracavernous self-injection.
Bandi G; Rajpurkar A; MacDonald MF; Dhabuwala CB
Urology; 2005 Apr; 65(4):797. PubMed ID: 15833537
[TBL] [Abstract][Full Text] [Related]
14. [The therapeutic and diagnostic potentials of the intra-corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction].
Mzo EB; Dmitriev DG
Ter Arkh; 1995; 67(10):45-8. PubMed ID: 8779105
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
Cawello W; Schweer H; Dietrich B; Seyberth HW; Albrecht D; Fox A; Hohmuth H
J Urol; 1997 Oct; 158(4):1403-7. PubMed ID: 9302131
[TBL] [Abstract][Full Text] [Related]
16. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
Polito M; d'Anzeo G; Conti A; Muzzonigro G
BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
[TBL] [Abstract][Full Text] [Related]
17. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction.
Rooney M; Pfister W; Mahoney M; Nelson M; Yeager J; Steidle C
J Sex Med; 2009 Feb; 6(2):520-34. PubMed ID: 19138370
[TBL] [Abstract][Full Text] [Related]
18. [The use of PGE1 in the treatment of erectile deficiency].
Arena F; Peracchia G; Di Stefano C; Cortellini P
Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
[TBL] [Abstract][Full Text] [Related]
19. Penile abscess and urethrocutaneous fistula following intracavernous injection: a case report.
Jinga V; Iconaru V
J Sex Med; 2012 Dec; 9(12):3270-3. PubMed ID: 23088765
[TBL] [Abstract][Full Text] [Related]
20. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice.
Rajpurkar A; Dhabuwala CB
J Urol; 2003 Jul; 170(1):159-63. PubMed ID: 12796670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
